JP2012530504A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012530504A5 JP2012530504A5 JP2012516746A JP2012516746A JP2012530504A5 JP 2012530504 A5 JP2012530504 A5 JP 2012530504A5 JP 2012516746 A JP2012516746 A JP 2012516746A JP 2012516746 A JP2012516746 A JP 2012516746A JP 2012530504 A5 JP2012530504 A5 JP 2012530504A5
- Authority
- JP
- Japan
- Prior art keywords
- rsv
- amino acid
- recombinant
- domain
- rsv antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000725643 Respiratory syncytial virus Species 0.000 claims 43
- 239000000427 antigen Substances 0.000 claims 28
- 102000036639 antigens Human genes 0.000 claims 28
- 108091007433 antigens Proteins 0.000 claims 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 229920001184 polypeptide Polymers 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 150000001413 amino acids Chemical class 0.000 claims 13
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims 12
- 230000037430 deletion Effects 0.000 claims 8
- 238000012217 deletion Methods 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 6
- 102000037865 fusion proteins Human genes 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000004961 Furin Human genes 0.000 claims 5
- 108090001126 Furin Proteins 0.000 claims 5
- 238000007792 addition Methods 0.000 claims 5
- 238000003776 cleavage reaction Methods 0.000 claims 5
- 230000004048 modification Effects 0.000 claims 5
- 238000012986 modification Methods 0.000 claims 5
- 230000007017 scission Effects 0.000 claims 5
- 230000013595 glycosylation Effects 0.000 claims 4
- 238000006206 glycosylation reaction Methods 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000002243 precursor Substances 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000006229 amino acid addition Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
- 238000005829 trimerization reaction Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21996409P | 2009-06-24 | 2009-06-24 | |
| US61/219,964 | 2009-06-24 | ||
| US33456810P | 2010-05-13 | 2010-05-13 | |
| US61/334,568 | 2010-05-13 | ||
| PCT/EP2010/059008 WO2010149745A1 (en) | 2009-06-24 | 2010-06-24 | Recombinant rsv antigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016005403A Division JP2016128457A (ja) | 2009-06-24 | 2016-01-14 | 組換えｒｓｖ抗原 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012530504A JP2012530504A (ja) | 2012-12-06 |
| JP2012530504A5 true JP2012530504A5 (enExample) | 2013-08-08 |
| JP6062245B2 JP6062245B2 (ja) | 2017-01-18 |
Family
ID=42670494
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012516746A Expired - Fee Related JP6062245B2 (ja) | 2009-06-24 | 2010-06-24 | 組換えｒｓｖ抗原 |
| JP2016005403A Pending JP2016128457A (ja) | 2009-06-24 | 2016-01-14 | 組換えｒｓｖ抗原 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016005403A Pending JP2016128457A (ja) | 2009-06-24 | 2016-01-14 | 組換えｒｓｖ抗原 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9492531B2 (enExample) |
| EP (1) | EP2445526B1 (enExample) |
| JP (2) | JP6062245B2 (enExample) |
| KR (1) | KR101696002B1 (enExample) |
| CN (1) | CN102481359B (enExample) |
| AU (2) | AU2010264688A1 (enExample) |
| BR (1) | BRPI1015917A2 (enExample) |
| CA (1) | CA2766211A1 (enExample) |
| CL (1) | CL2011003273A1 (enExample) |
| CO (1) | CO6480978A2 (enExample) |
| CR (1) | CR20120025A (enExample) |
| CY (1) | CY1117673T1 (enExample) |
| DK (1) | DK2445526T3 (enExample) |
| DO (1) | DOP2011000389A (enExample) |
| EA (1) | EA023054B1 (enExample) |
| ES (1) | ES2583257T3 (enExample) |
| HR (1) | HRP20160798T1 (enExample) |
| HU (1) | HUE028085T2 (enExample) |
| IL (1) | IL217013B (enExample) |
| MA (1) | MA33449B1 (enExample) |
| MX (1) | MX2012000035A (enExample) |
| PE (1) | PE20121541A1 (enExample) |
| PL (1) | PL2445526T3 (enExample) |
| PT (1) | PT2445526T (enExample) |
| SG (1) | SG176829A1 (enExample) |
| SI (1) | SI2445526T1 (enExample) |
| UA (1) | UA111141C2 (enExample) |
| WO (1) | WO2010149745A1 (enExample) |
| ZA (1) | ZA201109199B (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563002B2 (en) | 2007-12-24 | 2013-10-22 | Glaxosmithkline Biologicals, S.A. | Recombinant RSV antigens |
| ES2987238T3 (es) * | 2008-12-09 | 2024-11-14 | Novavax Inc | Proteínas F del RSV modificadas y métodos de su uso |
| SG176807A1 (en) * | 2009-06-24 | 2012-01-30 | Id Biomedical Corp Quebec | Vaccine |
| EP4183412B1 (en) | 2009-07-15 | 2024-08-14 | GlaxoSmithKline Biologicals SA | Rsv f protein compositions and methods for making same |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| RS56748B1 (sr) * | 2011-05-13 | 2018-03-30 | Glaxosmithkline Biologicals Sa | Pre-fuzioni rsv f antigeni |
| CN102294027A (zh) * | 2011-07-26 | 2011-12-28 | 昆明理工大学 | 一种呼吸道合胞病毒f2蛋白亚单位疫苗及其制备方法 |
| US9463236B2 (en) | 2011-08-29 | 2016-10-11 | Tokushima University | RSV mucosal vaccine |
| DK2750683T4 (da) * | 2011-10-03 | 2021-04-12 | Croda Int Plc | Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser |
| CN102743750B (zh) * | 2012-07-09 | 2013-11-20 | 江苏省农业科学院 | 一种复方免疫增强剂、禽用疫苗及其制备方法 |
| SI2879702T1 (sl) | 2012-08-01 | 2020-02-28 | Bavarian Nordic A/S | Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV) |
| SG11201500573RA (en) | 2012-08-06 | 2015-02-27 | Glaxosmithkline Biolog Sa | Method for eliciting in infants an immune response against rsv and b. pertussis |
| US20140037680A1 (en) * | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
| US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| EP4421177A3 (en) | 2013-03-13 | 2024-12-18 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Prefusion rsv f proteins and their use |
| US9060975B2 (en) | 2013-03-14 | 2015-06-23 | Mucosis Bv | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions |
| CN103204943B (zh) * | 2013-03-20 | 2014-07-23 | 中国科学院武汉病毒研究所 | 呼吸道合胞病毒F蛋白与Fc的融合蛋白及其用途 |
| MX2015013832A (es) * | 2013-04-08 | 2016-06-10 | Medimmune Llc | Composicion de vacuna y metodo de uso. |
| PT2988780T (pt) | 2013-04-25 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Polipeptídeos f de pré-fusão do rsv solúveis estabilizados |
| CN105408348B (zh) | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| SG11201600709TA (en) * | 2013-08-05 | 2016-02-26 | Glaxosmithkline Biolog Sa | Combination immunogenic compositions |
| US9322037B2 (en) * | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| EP3154576A1 (en) | 2014-06-13 | 2017-04-19 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
| CN107847580B (zh) | 2015-07-07 | 2022-08-12 | 扬森疫苗与预防公司 | 针对rsv的疫苗 |
| AU2016289496B2 (en) | 2015-07-07 | 2021-02-04 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| RU2723039C2 (ru) | 2015-12-23 | 2020-06-08 | Пфайзер Инк. | Мутанты белка f rsv |
| CN115960263A (zh) * | 2016-03-29 | 2023-04-14 | 美国政府(由卫生和人类服务部的部长所代表) | 取代修饰的融合前rsv f蛋白及其用途 |
| AU2017248018A1 (en) | 2016-04-05 | 2018-09-27 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
| MX2018012094A (es) | 2016-04-05 | 2019-01-10 | Janssen Vaccines & Prevention Bv | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas. |
| SG11201810078PA (en) | 2016-05-30 | 2018-12-28 | Janssen Vaccines & Prevention Bv | Stabilized pre-fusion rsv f proteins |
| WO2017207477A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
| CN107872643A (zh) * | 2016-09-23 | 2018-04-03 | 伊姆西Ip控股有限责任公司 | 用于视频监控系统的故障恢复方法和装置 |
| TWI683826B (zh) * | 2016-11-22 | 2020-02-01 | 國立臺灣大學 | 重組ｒｓｖ抗原 |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| EP3624851A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| CA3062549A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| CA3061278A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| GB2600652B (en) | 2017-05-30 | 2022-11-02 | Glaxosmithkline Biologicals Sa | Novel compositions |
| JP7356911B2 (ja) | 2017-06-14 | 2023-10-05 | ヴァイロメティックス アーゲー | 呼吸器合胞体ウイルスに対する予防のための環状ペプチド |
| AU2018333566A1 (en) | 2017-09-15 | 2020-02-27 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against RSV |
| KR102700187B1 (ko) * | 2017-09-29 | 2024-08-28 | 에스케이바이오사이언스(주) | 가용성 변형 호흡기 융합세포 바이러스 (ｒｓｖ) ｆ 단백질 항원 |
| JP2021504424A (ja) | 2017-12-01 | 2021-02-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニン精製 |
| CA3091558A1 (en) * | 2018-04-17 | 2019-10-24 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
| BR112021000965A2 (pt) | 2018-08-07 | 2021-04-27 | Glaxosmithkline Biologicals S.A. | processos e vacinas |
| PE20211469A1 (es) | 2018-11-13 | 2021-08-05 | Janssen Vaccines And Prevention B V | Proteinas f de prefusion del vrs estabilizadas |
| CA3121724A1 (en) | 2018-12-20 | 2020-06-25 | Virometix Ag | Lipopeptide building blocks and synthetic virus-like particles |
| WO2020175660A1 (ja) * | 2019-02-28 | 2020-09-03 | Ｋｍバイオロジクス株式会社 | Ｒｓｖ ｆ／ｇキメラワクチン |
| WO2020245207A1 (en) | 2019-06-05 | 2020-12-10 | Glaxosmithkline Biologicals Sa | Saponin purification |
| JP7822149B2 (ja) | 2020-10-02 | 2026-03-02 | ファイザー・インク | Ｒｓｖ ｆタンパク質生産のための細胞培養工程 |
| CN114685627A (zh) * | 2020-12-28 | 2022-07-01 | 广州更新生物医药科技有限公司 | 一种预防呼吸道合胞病毒的rAAV载体疫苗 |
| US20240228548A9 (en) | 2021-02-19 | 2024-07-11 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
| CN115772230A (zh) * | 2022-07-18 | 2023-03-10 | 青岛硕景生物科技有限公司 | 一种rsv重组抗原、其制备方法及应用 |
| KR20250054810A (ko) | 2022-09-29 | 2025-04-23 | 화이자 인코포레이티드 | Rsv f 단백질 삼량체를 포함하는 면역원성 조성물 |
| CN120153078A (zh) | 2022-10-27 | 2025-06-13 | 辉瑞大药厂 | 编码rsv-f的rna分子及含所述rna分子的疫苗 |
| WO2024089634A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
| JP2026500218A (ja) | 2022-12-11 | 2026-01-06 | ファイザー・インク | インフルエンザおよびｒｓｖに対する免疫原性組成物 |
| CN120548194A (zh) | 2023-01-18 | 2025-08-26 | 辉瑞公司 | 针对呼吸道疾病的疫苗 |
| US20260232787A1 (en) * | 2023-03-17 | 2026-08-13 | Westvac Biopharma Co., Ltd. | Vaccine against respiratory syncytial virus infection |
| TW202515531A (zh) | 2023-07-07 | 2025-04-16 | 美商輝瑞股份有限公司 | 兩親性ｔｌｒ７／８佐劑及其用途 |
| EP4520334A1 (en) | 2023-09-07 | 2025-03-12 | Mnemo Therapeutics | Methods and compositions for improving immune response |
| WO2025052001A1 (en) | 2023-09-07 | 2025-03-13 | Mnemo Therapeutics | Methods and compositions for improving immune response |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025163460A2 (en) | 2024-01-30 | 2025-08-07 | Pfizer Inc. | Vaccines against respiratory diseases |
| WO2025186719A1 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| WO2025263563A1 (ja) * | 2024-06-20 | 2025-12-26 | Ｋｍバイオロジクス株式会社 | ＲＳＶ ＦＧキメラｍＲＮＡワクチン |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| WO2026038177A1 (en) | 2024-08-16 | 2026-02-19 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| WO2026148356A1 (en) | 2025-01-06 | 2026-07-09 | BioNTech SE | Coronavirus and influenza immunogenic combinations |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
| IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US4707543A (en) | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
| US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5726292A (en) | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
| WO1989005823A1 (en) | 1987-12-23 | 1989-06-29 | The Upjohn Company | Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus |
| US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DE69313134T2 (de) | 1992-06-25 | 1998-02-26 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
| WO1994015968A1 (en) | 1993-01-08 | 1994-07-21 | The Upjohn Company | Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein |
| KR100310510B1 (ko) | 1993-03-23 | 2002-07-04 | 장 스테판느 | 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 |
| US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| PT729473E (pt) | 1993-11-17 | 2001-02-28 | Deutsche Om Arzneimittel Gmbh | Dissacaridos de glucosamina metodo para a sua preparacao composicao farmaceutica contendo os mesmos e sua utilizacao |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6060308A (en) * | 1997-09-04 | 2000-05-09 | Connaught Laboratories Limited | RNA respiratory syncytial virus vaccines |
| CA2302833C (en) | 1997-09-19 | 2007-05-08 | American Cyanamid Company | Peptides derived from the attachment (g) protein of respiratory syncytial virus |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| EP1089913A1 (fr) | 1998-06-08 | 2001-04-11 | SCA Emballage France | Emballage a remise a plat rapide |
| SK287073B6 (sk) | 1998-06-30 | 2009-11-05 | Om Pharma | N-Acyldipeptidový derivát, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje |
| ES2284287T3 (es) | 1998-10-16 | 2007-11-01 | Glaxosmithkline Biologicals S.A. | Sistemas adyuvantes y vacunas. |
| US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
| US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
| AU1581400A (en) | 1999-12-22 | 2001-07-03 | Om Pharma | Acyl pseudopeptides bearing a functionalised auxiliary spacer |
| US20040161846A1 (en) * | 2000-11-22 | 2004-08-19 | Mason Anthony John | Method of expression and agents identified thereby |
| DK1395669T3 (da) | 2001-01-26 | 2009-11-16 | Selexis Sa | Matriks bindingsregioner og fremgangsmåder til anvendelse af disse |
| EP1372706B1 (en) | 2001-03-09 | 2010-12-01 | ID Biomedical Corporation of Quebec | Proteosome-liposaccharide vaccine adjuvant |
| JP4331944B2 (ja) | 2001-04-17 | 2009-09-16 | 大日本住友製薬株式会社 | 新規アデニン誘導体 |
| DK1719511T3 (da) | 2001-11-16 | 2009-04-14 | Coley Pharm Group Inc | N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf |
| JP2006517974A (ja) | 2003-02-13 | 2006-08-03 | スリーエム イノベイティブ プロパティズ カンパニー | Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物 |
| US7368537B2 (en) | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
| KR101269656B1 (ko) | 2003-10-24 | 2013-05-30 | 셀렉시스 에스. 에이. | Ｍａｒ 서열의 복합 트랜스펙션 방법에 의한 포유동물 세포에서의 고효율 유전자 전달 및 발현 |
| FR2873378A1 (fr) | 2004-07-23 | 2006-01-27 | Pierre Fabre Medicament Sa | Complexes immunogenes, leur procede de preparation et leur utilisation dans des compositions pharmaceutiques |
| GB0422439D0 (en) | 2004-10-08 | 2004-11-10 | European Molecular Biology Lab Embl | Inhibitors of infection |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| WO2008061243A2 (en) * | 2006-11-16 | 2008-05-22 | Novavax, Inc. | Respiratory syncytial virus-virus like particle (vlps) |
| EP2181121A4 (en) | 2007-03-21 | 2012-07-11 | Id Biomedical Corp Quebec | CHIMÄRE ANTIGENE |
| WO2008154456A2 (en) * | 2007-06-06 | 2008-12-18 | Nationwide Children's Hospital, Inc. | Methods and compositions relating to viral fusion proteins |
| US8563002B2 (en) * | 2007-12-24 | 2013-10-22 | Glaxosmithkline Biologicals, S.A. | Recombinant RSV antigens |
| KR20110045008A (ko) | 2008-07-18 | 2011-05-03 | 아이디 바이오메디컬 코포레이션 오브 퀘벡 | 키메라 호흡기 세포융합 바이러스 폴리펩티드 항원 |
| SG176807A1 (en) | 2009-06-24 | 2012-01-30 | Id Biomedical Corp Quebec | Vaccine |
-
2010
- 2010-06-24 PL PL10724879T patent/PL2445526T3/pl unknown
- 2010-06-24 PE PE2011002168A patent/PE20121541A1/es not_active Application Discontinuation
- 2010-06-24 MX MX2012000035A patent/MX2012000035A/es active IP Right Grant
- 2010-06-24 CN CN201080037770.3A patent/CN102481359B/zh not_active Expired - Fee Related
- 2010-06-24 JP JP2012516746A patent/JP6062245B2/ja not_active Expired - Fee Related
- 2010-06-24 AU AU2010264688A patent/AU2010264688A1/en not_active Abandoned
- 2010-06-24 MA MA34557A patent/MA33449B1/fr unknown
- 2010-06-24 BR BRPI1015917A patent/BRPI1015917A2/pt not_active Application Discontinuation
- 2010-06-24 HR HRP20160798TT patent/HRP20160798T1/hr unknown
- 2010-06-24 KR KR1020127001782A patent/KR101696002B1/ko not_active Expired - Fee Related
- 2010-06-24 DK DK10724879.1T patent/DK2445526T3/en active
- 2010-06-24 ES ES10724879.1T patent/ES2583257T3/es active Active
- 2010-06-24 SI SI201031234A patent/SI2445526T1/sl unknown
- 2010-06-24 SG SG2011092319A patent/SG176829A1/en unknown
- 2010-06-24 EP EP10724879.1A patent/EP2445526B1/en active Active
- 2010-06-24 HU HUE10724879A patent/HUE028085T2/en unknown
- 2010-06-24 WO PCT/EP2010/059008 patent/WO2010149745A1/en not_active Ceased
- 2010-06-24 EA EA201270063A patent/EA023054B1/ru not_active IP Right Cessation
- 2010-06-24 CA CA2766211A patent/CA2766211A1/en not_active Abandoned
- 2010-06-24 UA UAA201200714A patent/UA111141C2/uk unknown
- 2010-06-24 US US13/378,391 patent/US9492531B2/en not_active Expired - Fee Related
- 2010-06-24 PT PT107248791T patent/PT2445526T/pt unknown
-
2011
- 2011-12-14 ZA ZA2011/09199A patent/ZA201109199B/en unknown
- 2011-12-14 DO DO2011000389A patent/DOP2011000389A/es unknown
- 2011-12-15 IL IL217013A patent/IL217013B/en not_active IP Right Cessation
- 2011-12-22 CL CL2011003273A patent/CL2011003273A1/es unknown
- 2011-12-29 CO CO11181053A patent/CO6480978A2/es unknown
-
2012
- 2012-01-16 CR CR20120025A patent/CR20120025A/es unknown
-
2014
- 2014-07-03 AU AU2014203636A patent/AU2014203636C1/en not_active Ceased
-
2016
- 2016-01-14 JP JP2016005403A patent/JP2016128457A/ja active Pending
- 2016-06-21 CY CY20161100557T patent/CY1117673T1/el unknown